This Phase 1/2 clinical trial is investigating a new targeted treatment called NBM-BMX for people with metastatic uveal melanoma, a type of eye cancer that has spread to other parts of the body. NBM-BMX is designed to target a pathway involved in tumour growth and cancer cell survival, with researchers hoping it may help slow down or shrink tumours in patients with advanced disease.
The study aims to determine the safest and most effective dose of NBM-BMX, while also assessing how the drug is processed by the body (pharmacokinetics, or PK), its side effects, and its potential anti-tumour activity. Participants will take NBM-BMX as an oral capsule twice daily in repeated 28-day treatment cycles and will undergo regular scans, blood tests, and safety monitoring throughout the trial.
NBM-BMX is a selective HDAC8 inhibitor, a type of treatment targeting epigenetic changes linked to the development and progression of uveal melanoma. Early research and previous Phase 1 studies in advanced solid tumours have suggested the drug is generally well tolerated and may show activity in metastatic uveal melanoma. The treatment has also received FDA Fast Track and Orphan Drug designations in the United States, highlighting its potential as a promising therapy for this rare cancer.
At the present time, there are no active UK locations listed for this trial (NCT07136181), and we are not currently aware of any plans for the study to open at UK sites.